MedTrace Logo

Antidepressants and Bone Mineral Density

NCT02179268 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 203

Last updated 2014-07-01

No results posted yet for this study

Summary

The aim of this five arm randomized trial was thus to compare selective serotonin reuptake inhibitor (SSRI)sertraline and citalopram to a dual reuptake inhibitor venlafaxine, a nor-adrenaline reuptake inhibitor reboxetine and a control group receiving placebo, with the primary endpoint being bone mineral density, and secondary endpoints being bone turnover markers.

Conditions

  • Bone Mineral Density Quantitative Trait Locus 7

Interventions

DRUG

sertraline

50mg, 50-150mg/d,qd for one year

DRUG

citalopram

20mg, 20-40mg/d,qd,for one year

DRUG

venlafaxine

venlafaxine,25mg, 75-100mg/d, bid, for one year

DRUG

reboxetine

reboxetine,4mg, 4-8mg/d,qd for one year

BEHAVIORAL

control

50min, every week for three months, every month, for nine months

Sponsors & Collaborators

  • Guiyang Medical University

    lead OTHER

Principal Investigators

  • yiming wang, Ph.D · World Health Organization

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
48 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2014-04-30
Completion
2014-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02179268 on ClinicalTrials.gov